Treatment of Severe Alcohol Withdrawal

  title={Treatment of Severe Alcohol Withdrawal},
  author={Kyle J Schmidt and Mitesh Doshi and Jenna M. Holzhausen and Allycia Natavio and Megan L. Cadiz and Jim E. Winegardner},
  journal={Annals of Pharmacotherapy},
  pages={389 - 401}
Objective: Approximately 50% of patients with alcohol dependence experience alcohol withdrawal. [] Key Method Data Sources: PubMed (January 1960 to October 2015) was searched using the search terms alcohol withdrawal, delirium tremens, intensive care, and refractory. Supplemental references were generated through review of identified literature citations. Study Selection and Data Extraction:

Figures and Tables from this paper

Battle of the Benzodiazepines: Comparison of Treatment Outcomes for Alcohol Withdrawal Syndrome: Lorazepam vs Chlordiazepoxide - A Literature Review

It is concluded that the use of lorazepam can be more advantageous than traditionally accepted treatments due to its safety profile among patients with liver disease, promising abilities to decrease the time to complete resolution of symptoms, and a potentially easier transfer to sobriety.

The emergency medicine management of severe alcohol withdrawal

Clinical Management of the Alcohol Withdrawal Syndrome.

Key elements of the clinical management of Medically assisted withdrawal, necessary adjustments for pregnancy and older adults, likely outcome of an episode of MAW, factors that might prevent completion of the MAW process, and ways of overcoming barriers to ongoing treatment of alcohol use disorder are discussed.

Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA‐Ar Protocol

A phenobarbital protocol for the treatment of alcohol withdrawal is an effective alternative to the standard‐of‐care protocol of symptom‐triggered benzodiazepine therapy.

Update on Phenobarbital for Alcohol Withdrawal Syndrome in Intensive Care

Powered randomized controlled trials with large populations are required, yet phenobarbital can be used to safely to treat AWS, and it is safe for patients without severe hepatic impairment, has a better mechanism of action and longer half-life than benzodiazepines, and leads to less delirium and agitation.

Efficacy and Safety of Anticonvulsants for the Inpatient Treatment of Alcohol Withdrawal Syndrome: A Systematic Review and Meta-analysis.

The routine use of AED is not suggested in the treatment of patients with moderate or severe AWS unless indicated for comorbidity (weak recommendation against using moderate quality of evidence).

Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol

A task force of specialists drew up recommendations for the treatment of alcohol withdrawal syndrome with the following main results: while mild AWS may not require treatment, moderate and severe AWS need to be pharmacologically treated.



Management of alcohol withdrawal delirium. An evidence-based practice guideline.

Control of agitation should be achieved using parenteral rapid-acting sedative-hypnotic agents that are cross-tolerant with alcohol, andequate doses should be used to maintain light somnolence for the duration of delirium.

Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal.

Benzodiazepines are suitable agents for alcohol withdrawal, with choice among different agents guided by duration of action, rapidity of onset, and cost, and Dosage should be individualized, based on withdrawal severity measured by withdrawal scales.

Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial.

Symptom-triggered benzodiazepine treatment for alcohol withdrawal is safe, comfortable, and associated with a decrease in the quantity of medication and duration of treatment.

Alcohol, Nicotine, and Iatrogenic Withdrawals in the ICU

The role of currently published alcohol withdrawal syndrome pharmacologic strategies (benzodiazepines, ethanol, clomethiazole, antipsychotics, barbiturates, propofol, and dexmedetomidine) is detailed and recommendations as to nicotine replacement therapy and management of iatrogenic drug withdrawal in ICU patients are recommended.

Evaluation of Adjunctive Ketamine to Benzodiazepines for Management of Alcohol Withdrawal Syndrome

Ketamine appears to reduce BZD requirements and is well tolerated at low doses and Prospective dose range evaluations in the management of AWS would be helpful in determining its place as an adjunctive agent.

Phenobarbital Treatment in a Patient with Resistant Alcohol Withdrawal Syndrome

The administration of phenobarbital in this patient allowed improved symptom control, minimized the potential for propylene glycol toxicity, was not associated with respiratory depression, and facilitated successful weaning of benzodiazepines.

Use of Propofol-Containing Versus Benzodiazepine Regimens for Alcohol Withdrawal Requiring Mechanical Ventilation

Propofol and Benzodiazepine-treated patients with AWS requiring mechanical ventilation experienced similar days of AWS symptoms, length of stay, and mechanical ventilation.

Use of propofol infusion in alcohol withdrawal-induced refractory delirium tremens.

This study suggests that treatment with propofol is viable in refractory delirium tremens, and establishing indication, dose, duration, and long-term effects of prop ofol treatment of deliria tremens requires further investigation.

Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial.

Symptom-triggered therapy individualizes treatment, decreases both treatment duration and the amount of benzodiazepine used, and is as efficacious as standard fixed-schedule therapy for alcohol withdrawal.